![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: ARFGAP2 |
Gene summary for ARFGAP2 |
![]() |
Gene information | Species | Human | Gene symbol | ARFGAP2 | Gene ID | 84364 |
Gene name | ADP ribosylation factor GTPase activating protein 2 | |
Gene Alias | IRZ | |
Cytomap | 11p11.2 | |
Gene Type | protein-coding | GO ID | GO:0006810 | UniProtAcc | G5E9L0 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
84364 | ARFGAP2 | LZE4T | Human | Esophagus | ESCC | 2.78e-16 | 3.76e-01 | 0.0811 |
84364 | ARFGAP2 | LZE7T | Human | Esophagus | ESCC | 8.96e-08 | 5.22e-01 | 0.0667 |
84364 | ARFGAP2 | LZE8T | Human | Esophagus | ESCC | 4.61e-09 | 2.89e-01 | 0.067 |
84364 | ARFGAP2 | LZE20T | Human | Esophagus | ESCC | 4.78e-04 | 1.94e-01 | 0.0662 |
84364 | ARFGAP2 | LZE22T | Human | Esophagus | ESCC | 4.87e-03 | 2.65e-01 | 0.068 |
84364 | ARFGAP2 | LZE24T | Human | Esophagus | ESCC | 8.29e-18 | 3.75e-01 | 0.0596 |
84364 | ARFGAP2 | LZE6T | Human | Esophagus | ESCC | 1.73e-05 | 1.98e-01 | 0.0845 |
84364 | ARFGAP2 | P1T-E | Human | Esophagus | ESCC | 1.08e-02 | 2.50e-01 | 0.0875 |
84364 | ARFGAP2 | P2T-E | Human | Esophagus | ESCC | 2.80e-23 | 5.01e-01 | 0.1177 |
84364 | ARFGAP2 | P4T-E | Human | Esophagus | ESCC | 6.54e-11 | 2.60e-01 | 0.1323 |
84364 | ARFGAP2 | P5T-E | Human | Esophagus | ESCC | 8.20e-13 | 2.45e-01 | 0.1327 |
84364 | ARFGAP2 | P8T-E | Human | Esophagus | ESCC | 1.14e-18 | 3.61e-01 | 0.0889 |
84364 | ARFGAP2 | P9T-E | Human | Esophagus | ESCC | 9.81e-20 | 2.98e-01 | 0.1131 |
84364 | ARFGAP2 | P10T-E | Human | Esophagus | ESCC | 1.19e-18 | 3.79e-01 | 0.116 |
84364 | ARFGAP2 | P11T-E | Human | Esophagus | ESCC | 2.39e-20 | 8.14e-01 | 0.1426 |
84364 | ARFGAP2 | P12T-E | Human | Esophagus | ESCC | 3.49e-16 | 4.00e-01 | 0.1122 |
84364 | ARFGAP2 | P15T-E | Human | Esophagus | ESCC | 1.08e-24 | 5.68e-01 | 0.1149 |
84364 | ARFGAP2 | P16T-E | Human | Esophagus | ESCC | 2.01e-24 | 4.62e-01 | 0.1153 |
84364 | ARFGAP2 | P17T-E | Human | Esophagus | ESCC | 6.10e-11 | 3.98e-01 | 0.1278 |
84364 | ARFGAP2 | P19T-E | Human | Esophagus | ESCC | 1.07e-10 | 5.51e-01 | 0.1662 |
Page: 1 2 3 4 5 6 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:004819321 | Liver | HCC | Golgi vesicle transport | 217/7958 | 296/18723 | 2.58e-27 | 1.02e-24 | 217 |
GO:001605021 | Liver | HCC | vesicle organization | 194/7958 | 300/18723 | 5.58e-15 | 3.97e-13 | 194 |
GO:000690021 | Liver | HCC | vesicle budding from membrane | 53/7958 | 61/18723 | 7.38e-13 | 3.80e-11 | 53 |
GO:005165621 | Liver | HCC | establishment of organelle localization | 226/7958 | 390/18723 | 4.15e-10 | 1.34e-08 | 226 |
GO:005165021 | Liver | HCC | establishment of vesicle localization | 103/7958 | 161/18723 | 2.94e-08 | 6.69e-07 | 103 |
GO:00481991 | Liver | HCC | vesicle targeting, to, from or within Golgi | 20/7958 | 21/18723 | 4.57e-07 | 7.50e-06 | 20 |
GO:005164821 | Liver | HCC | vesicle localization | 107/7958 | 177/18723 | 1.05e-06 | 1.57e-05 | 107 |
GO:000690311 | Liver | HCC | vesicle targeting | 34/7958 | 45/18723 | 6.75e-06 | 8.08e-05 | 34 |
GO:000690111 | Liver | HCC | vesicle coating | 16/7958 | 17/18723 | 1.15e-05 | 1.31e-04 | 16 |
GO:004819411 | Liver | HCC | Golgi vesicle budding | 9/7958 | 10/18723 | 2.79e-03 | 1.31e-02 | 9 |
GO:004819315 | Oral cavity | OSCC | Golgi vesicle transport | 209/7305 | 296/18723 | 1.39e-28 | 6.30e-26 | 209 |
GO:005165610 | Oral cavity | OSCC | establishment of organelle localization | 239/7305 | 390/18723 | 2.46e-19 | 3.31e-17 | 239 |
GO:00160508 | Oral cavity | OSCC | vesicle organization | 189/7305 | 300/18723 | 2.40e-17 | 2.14e-15 | 189 |
GO:000690019 | Oral cavity | OSCC | vesicle budding from membrane | 49/7305 | 61/18723 | 4.73e-11 | 1.50e-09 | 49 |
GO:00069037 | Oral cavity | OSCC | vesicle targeting | 38/7305 | 45/18723 | 4.49e-10 | 1.19e-08 | 38 |
GO:00516509 | Oral cavity | OSCC | establishment of vesicle localization | 101/7305 | 161/18723 | 8.79e-10 | 2.17e-08 | 101 |
GO:00516489 | Oral cavity | OSCC | vesicle localization | 105/7305 | 177/18723 | 3.30e-08 | 6.30e-07 | 105 |
GO:00481995 | Oral cavity | OSCC | vesicle targeting, to, from or within Golgi | 19/7305 | 21/18723 | 1.41e-06 | 1.86e-05 | 19 |
GO:00069016 | Oral cavity | OSCC | vesicle coating | 16/7305 | 17/18723 | 3.07e-06 | 3.72e-05 | 16 |
GO:00481946 | Oral cavity | OSCC | Golgi vesicle budding | 9/7305 | 10/18723 | 1.36e-03 | 6.62e-03 | 9 |
Page: 1 2 3 4 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa04144210 | Esophagus | ESCC | Endocytosis | 186/4205 | 251/8465 | 9.74e-16 | 4.66e-14 | 2.39e-14 | 186 |
hsa0414437 | Esophagus | ESCC | Endocytosis | 186/4205 | 251/8465 | 9.74e-16 | 4.66e-14 | 2.39e-14 | 186 |
hsa0414412 | Liver | Cirrhotic | Endocytosis | 119/2530 | 251/8465 | 2.33e-09 | 4.56e-08 | 2.81e-08 | 119 |
hsa0414413 | Liver | Cirrhotic | Endocytosis | 119/2530 | 251/8465 | 2.33e-09 | 4.56e-08 | 2.81e-08 | 119 |
hsa0414422 | Liver | HCC | Endocytosis | 178/4020 | 251/8465 | 2.03e-14 | 5.22e-13 | 2.91e-13 | 178 |
hsa0414432 | Liver | HCC | Endocytosis | 178/4020 | 251/8465 | 2.03e-14 | 5.22e-13 | 2.91e-13 | 178 |
hsa0414427 | Oral cavity | OSCC | Endocytosis | 174/3704 | 251/8465 | 9.42e-17 | 4.51e-15 | 2.29e-15 | 174 |
hsa04144112 | Oral cavity | OSCC | Endocytosis | 174/3704 | 251/8465 | 9.42e-17 | 4.51e-15 | 2.29e-15 | 174 |
hsa0414428 | Oral cavity | LP | Endocytosis | 121/2418 | 251/8465 | 1.89e-11 | 3.70e-10 | 2.38e-10 | 121 |
hsa0414436 | Oral cavity | LP | Endocytosis | 121/2418 | 251/8465 | 1.89e-11 | 3.70e-10 | 2.38e-10 | 121 |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ARFGAP2 | SNV | Missense_Mutation | novel | c.101C>A | p.Pro34Gln | p.P34Q | Q8N6H7 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-A2-A25A-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Cytoxan | SD |
ARFGAP2 | SNV | Missense_Mutation | c.23N>T | p.Thr8Ile | p.T8I | Q8N6H7 | protein_coding | tolerated(0.05) | benign(0.172) | TCGA-AR-A24H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD | |
ARFGAP2 | insertion | Frame_Shift_Ins | novel | c.210_211insTTCTTGAGAATCACCCGTAGCACGCGCTG | p.Asn71PhefsTer10 | p.N71Ffs*10 | Q8N6H7 | protein_coding | TCGA-A8-A09A-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | ||
ARFGAP2 | SNV | Missense_Mutation | novel | c.869A>C | p.Lys290Thr | p.K290T | Q8N6H7 | protein_coding | deleterious(0.05) | probably_damaging(0.987) | TCGA-EA-A410-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
ARFGAP2 | SNV | Missense_Mutation | c.1417N>T | p.His473Tyr | p.H473Y | Q8N6H7 | protein_coding | tolerated(0.06) | benign(0.027) | TCGA-LP-A7HU-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
ARFGAP2 | SNV | Missense_Mutation | rs372871965 | c.566C>T | p.Pro189Leu | p.P189L | Q8N6H7 | protein_coding | tolerated(0.06) | benign(0.017) | TCGA-AA-3947-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
ARFGAP2 | SNV | Missense_Mutation | c.648G>T | p.Lys216Asn | p.K216N | Q8N6H7 | protein_coding | deleterious(0) | possibly_damaging(0.649) | TCGA-CA-6718-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | PD | |
ARFGAP2 | SNV | Missense_Mutation | novel | c.1517N>C | p.Leu506Pro | p.L506P | Q8N6H7 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-G4-6302-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ARFGAP2 | SNV | Missense_Mutation | rs760907325 | c.278N>A | p.Arg93His | p.R93H | Q8N6H7 | protein_coding | tolerated(0.73) | benign(0.017) | TCGA-G4-6302-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ARFGAP2 | deletion | Frame_Shift_Del | rs772728725 | c.276delN | p.Arg93AlafsTer43 | p.R93Afs*43 | Q8N6H7 | protein_coding | TCGA-5M-AAT6-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Unknown | Unknown | PD |
Page: 1 2 3 4 5 6 7 8 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |